| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AACAP: Guanfacine Effective For AD/HD And Tic Disorder By Lara Pullen Special to DG News CHICAGO, IL -- October 26, 1999 -- Although stimulants are the first line of treatment for children with attention deficit/hyperactivity disorder (AD/HD), approximately 30 percent of children fail to respond to stimulants and may demonstrate de novo emergence or worsening of tics following stimulant exposure. Guanfacine appears to be a safe and effective treatment for these children.
At the 46th annual meeting of the American Academy of Child and Adolescent Psychiatry, Dr. Lawrence D. Scahill, of the Yale Child Study Center, described the results of an eight-week, randomized, placebo-controlled trial. The purpose of the trial was to evaluate the efficacy and safety of guanfacine in children with AD/HD and a tic disorder. The trial comprised 34 medication-free subjects (31 boys and 3 girls) ranging in age from seven to 14 years (mean of 10 years). Primary outcome measures were the DuPaul AD/HD Rating Scale (assessed by the teacher) and the Clinical Global Improvement Score (assessed by the blinded clinician). At endpoint, nine of 17 subjects on guanfacine were blindly rated as "much improved" or "very much improved" compared to 0 of 17 on placebo. Guanfacine was associated with a 37 percent improvement of AD/HD symptoms.
|